Clinical trials: Cancer of Gastrointestinal Tract
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Neoplasms
Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies
The primary objectives of the Phase I study 15404 are to evaluate the safety, tolerability and pharmacokinetics of BAY94-9343 given once every 3 weeks in Japanese subjects with advanced, refractory solid tumors.
- Trial name
- NCT02485119
- Testing
- BAY94-9343
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Solid Tumors
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
The purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic solid tumors.
- Trial name
- NCT03361228
- Testing
- INCB001158, Epacadostat, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Incyte Corporation
Breast Cancer, Lung Cancer
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
The Carevive registry collects patient characteristics, patient symptoms, and treatment experience data from patients receiving cancer treatment for breast, lung, GI or multiple myeloma.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma
- Trial name
- NCT05587972
- Testing
- survey
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Carevive Systems, Inc.
Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies
A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
The purpose of this study is to evaluate the safety of TAK-164 and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and schedule.
- Trial name
- NCT03449030
- Testing
- TAK-164, 89Zr-TAK-164
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are.
- Conditions
- Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT04254107
- Testing
- SEA-TGT, sasanlimab, brentuximab vedotin
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 133 people
- Sponsor
- Seagen Inc.
Solid Tumor, Non-Small-Cell Lung Cancer
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS.
- Conditions
- Solid Tumor, Non-Small-Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT07094204
- Testing
- ASP5834, panitumumab
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 404 people
- Sponsor
- Astellas Pharma Inc
Colorectal Cancer, Non-Small Cell Lung Cancer
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in…
- Trial name
- ARIES (NCT00388206)
- Volunteers
- 3,998 people
- Sponsor
- Genentech, Inc.
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Head and Neck Cancers, Breast Cancer
Feasibility Study of CBCT for IGRT in Cancer Patients
Cone beam computed tomography (CBCT) is an imaging technology that is incorporated into many modern radiation therapy systems. The quality of conventional CBCT is good enough to align patients for their daily radiation therapy…
- Conditions
- Head and Neck Cancers, Breast Cancer, Thoracic Cancers, Liver Cancer
- Trial name
- NCT06681233
- Testing
- Comparison of HyperSight CBCT imaging to conventional CBCT imaging.
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Varian, a Siemens Healthineers Company
Colorectal Cancer, Head and Neck Cancer
Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib
This is an open-label, phase 1, non-randomised, non-controlled trial, carried out in two centres on patients with advanced cancer expressing EGFR.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer (NSCLC)
- Trial name
- NCT00820417
- Testing
- Cetuximab/Gefitinib combination and/or monotherapy
- Where
- 2 sites in Belgium, Spain
- Volunteers
- 63 people
- Sponsor
- Harrison Clinical Research
Gastrointestinal Cancer, Prostate Cancer
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.
- Conditions
- Gastrointestinal Cancer, Prostate Cancer, Genital Neoplasms, Female
- Trial name
- NCT00332280
- Testing
- AMT2003
- Where
- 2 sites in Bosnia and Herzegovina, Germany
- Volunteers
- 67 people
- Sponsor
- Auron Healthcare GmbH
Solid Tumor, Biliary Tract Cancer
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT05784688
- Testing
- TU2218 + KEYTRUDA® (Pembrolizumab)
- Where
- 11 sites in United States, South Korea
- Volunteers
- 140 people
- Sponsor
- TiumBio Co., Ltd.
Colorectal Cancer, CRC
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors combined with Standard(s) of Care (SOC) or with novel agents.
- Conditions
- Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC
- Trial name
- NCT06445062
- Testing
- RMC-6236, mFOLFOX6 regimen, bevacizumab
- Where
- 32 sites in United States
- Volunteers
- 1,130 people
- Sponsor
- Revolution Medicines, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Solid Tumors
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This is an open-label, multicenter Phase 2 study evaluating Navlimetostat (BMS-986504) in participants with advanced and/or metastatic solid tumors that have MTAP deletion.
- Trial name
- NCT07492680
- Testing
- Navlimetostat, Daraxonrasib, Temozolomide
- Where
- 58 sites in United States, Belgium and 11 more
- Volunteers
- 254 people
- Sponsor
- Bristol-Myers Squibb
Solid Tumor, Adult, Colorectal Cancer
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma
- Trial name
- NCT06270082
- Testing
- IK-595
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- Ikena Oncology
Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC)
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
This study is a multicenter, open-label, phase II clinical trial evaluating the combination of SSGJ-706 with standard therapy for advanced gastrointestinal tumors.
- Conditions
- Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Oesophageal Cancer
- Trial name
- NCT07233850
- Testing
- SSGJ-706+XELOX, SSGJ-706+Bevacizumab+XELOX, SSGJ-706+AG
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Melanoma (Skin), Triple-Negative Breast Cancer
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to…
- Conditions
- Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma
- Trial name
- NCT05492682
- Testing
- PeptiCRAd-1, Cyclophosphamide, Pembrolizumab
- Where
- 7 sites in Germany, Italy
- Volunteers
- 15 people
- Sponsor
- Valo Therapeutics Oy
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.